双重抑制XIIa因子和XIa因子产生一个协同的抗凝效应
Shuai Jiang1, Yitong Li1, Jiali Zhang1
1School of Life Science and Technology, China Pharmaceutical University, Nanjing, China ; and.
Journal of cardiovascular pharmacology
|June 26, 2024
概括
结合FXIa和FXIIa抑制剂提供了一个新的抗凝固剂策略. 这种双重抑制在预防血栓形成方面表现出协同效应,而不会增加出血风险,解决了一个关键的未满足需求.
科学领域:
- 血栓形成和血液静止.
- 药理学 药理学是指药理学的学科.
背景情况:
- 预防血栓形成的一个重大未满足的需求是抗凝固药疗法,其出血风险最小.
- XIa因子 (FXIa) 和XIIa因子 (FXIIa) 抑制剂正在研究其潜在的低出血风险.
- 结合FXIa和FXIIa抑制的协同抗凝剂作用以前没有被探索过.
研究的目的:
- 研究结合FXIa抑制剂 (PN2KPI) 和FXIIa抑制剂 (Infestin4) 的协同抗凝剂作用.
- 在临床前血栓形成模型中评估这种双重抑制的疗效和出血风险.
主要方法:
- 激活的部分血栓形成时间 (aPTT) 试验被用来评估抗凝作用.
- 使用SynergyFinder工具分析PN2KPI和Infestin4.4的协同效应.
- 使用FeCl3诱导的动脉血栓和暂时的中脑动脉封闭的小鼠模型.
主要成果:
- 在FXIa抑制剂PN2KPI和FXIIa抑制剂Infestin4.4之间确定了协同抗凝效应.
- 结合PN2KPI (28.57%的有效剂量) 和Infestin4 (6.25%的有效剂量) 在体内显著防止凝血.
- 使用PN2KPI和Infestin4的双抑制没有导致任何观察到的出血风险.
结论:
- 联合抑制FXIa和FXIIa显示出协同作用的抗凝固作用.
- 这种双重抑制策略代表了预防血栓形成的有前途的方法,可能改善了关于出血风险的安全性.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Extrinsic and Intrinsic Pathways of Hemostasis
7.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.0K
Combined Effects of Drugs: Antagonism
8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K


